Literature DB >> 2194428

Measurement and clinical importance of antibodies to glycosphingolipids.

D M Marcus1.   

Abstract

Measurement of antibodies against gangliosides and other glycosphingolipids (GSLs) is technically demanding because of their low affinity for antigen. A recent workshop, in which twelve laboratories received a coded panel of sera containing anti-GM1 antibodies, demonstrated that the immunoassays varied widely in sensitivity and in criteria employed for a positive test. The fine specificity of anti-GSL antibodies should be characterized by analyzing their reactivity with a panel of GSLs with related structures. High-titer monoclonal IgM antibodies against gangliosides and sulfated carbohydrates appear to cause neuropathy in some patients. Low-titer polyclonal antibodies against gangliosides occur frequently in a variety of diseases, including autoimmune diseases without neurological symptoms. It is unclear whether these polyclonal antibodies are a primary manifestation or a consequence of the disease, and their clinical importance is uncertain at present.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2194428     DOI: 10.1002/ana.410270714

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  3 in total

1.  Stage-specific expression of fuco-neolacto- (Lewis X) and ganglio-series neutral glycosphingolipids during brain development: characterization of Lewis X and related glycosphingolipids in bovine, human and rat brain.

Authors:  S Dasgupta; E L Hogan; S S Spicer
Journal:  Glycoconj J       Date:  1996-06       Impact factor: 2.916

2.  Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors.

Authors:  C O Yun; K F Nolan; E J Beecham; R A Reisfeld; R P Junghans
Journal:  Neoplasia       Date:  2000 Sep-Oct       Impact factor: 5.715

3.  Autoantibodies against Forssman glycolipids in Graves' disease and Hashimoto's thyroiditis.

Authors:  T Ariga; T Yoshida; T Mimori; R K Yu
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.